Hepion Pharmaceuticals In... (HEPA)
Company Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States.
It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms.
The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019.
Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Country | United States |
IPO Date | Feb 10, 2014 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 22 |
CEO | John Patrick Brancaccio CPA |
Contact Details
Address: 399 Thornall Street Edison, New Jersey United States | |
Website | https://www.hepionpharma.com |
Stock Details
Ticker Symbol | HEPA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001583771 |
CUSIP Number | 426897401 |
ISIN Number | US4268974015 |
Employer ID | 46-2783806 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
John Patrick Brancaccio CPA | Interim Chief Executive Officer, Interim Chief Financial Officer & Chairman of the Board |
Sharen Pyatetskaya | Director of Investor Relations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 01, 2025 | NT 10-K | Filing |
Mar 20, 2025 | 8-K | Current Report |
Mar 19, 2025 | 8-K | Current Report |
Mar 10, 2025 | 8-K | Current Report |
Mar 04, 2025 | 8-K | Current Report |
Feb 07, 2025 | DEF 14A | Filing |
Feb 07, 2025 | ARS/A | [Amend] Filing |
Feb 07, 2025 | ARS | Filing |
Jan 27, 2025 | PRE 14A | Filing |
Jan 27, 2025 | SCHEDULE 13G | Filing |